The combination of dasatinib with paclitaxel or gemcitabine significantly enhances the inhibition of cell viability, proliferation, migration, and colony formation in PaC cell lines by targeting p-SRC, p-STAT3, p-AKT, and p-ERK39. The gene discussed is SRC; the disease is gonorrhea.